Managed Access Programs for CTL019, Tisagenlecleucel

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

NCT05826535 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Retreatment With CTL019/CTL119

NCT04419909 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390 ·Status: RECRUITING ·Phase: PHASE1

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

NCT06079164 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Treatment for Advanced B-Cell Lymphoma

NCT01859819 ·Status: COMPLETED ·Phase: PHASE2

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03123393 ·Status: TERMINATED ·Phase: PHASE2

Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel

NCT05199961 ·Status: TERMINATED ·Phase: NA

DALY II USA/ MB-CART2019.1 for DLBCL

NCT04792489 ·Status: RECRUITING ·Phase: PHASE2

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02957019 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Outpatient Epcoritamab as 2L in NTE R/R DLBCL

NCT06811272 ·Status: RECRUITING ·Phase: PHASE2

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01197560 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab

NCT00561379 ·Status: COMPLETED ·Phase: NA

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

NCT01014208 ·Status: COMPLETED ·Phase: PHASE3

Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

NCT03870945 ·Status: COMPLETED ·Phase: PHASE1

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT06014762 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib

NCT04757259 ·Status: NO_LONGER_AVAILABLE

Dynamic CtDNA-guided Targeted Therapy in DLBCL

NCT06748521 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

NCT06104592 ·Status: RECRUITING ·Phase: PHASE2

Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab

NCT01119794 ·Status: TERMINATED ·Phase: PHASE2

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT00968331 ·Status: TERMINATED ·Phase: PHASE2

Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

NCT05014100 ·Status: UNKNOWN ·Phase: PHASE2

Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02926833 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)

NCT01502982 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

NCT01238692 ·Status: COMPLETED ·Phase: PHASE2

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT04806035 ·Status: TERMINATED ·Phase: PHASE1